patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_420662 | REC_0004801 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 5.3 | 78 | female | 1 | 44 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 7.4 | true | MSS | 2026-03-15T05:35:58.034038+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_102151 | REC_0004802 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 16.2 | 66 | female | 1 | 16 | 4.6 | 7 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.034272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_219406 | REC_0004803 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 16 | 6.4 | 52 | male | 0 | 8 | 5.9 | 3 | pembrolizumab 200 mg q3w | 10.2 | true | MSS | 2026-03-15T05:35:58.034502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623592 | REC_0004804 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 11 | 11.3 | 62 | female | 1 | 13 | 6 | 0 | sotorasib 960 mg daily | 63.3 | true | MSS | 2026-03-15T05:35:58.034736+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_455112 | REC_0004805 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 18.1 | 64 | female | 1 | 11 | 5.2 | 7 | sotorasib 960 mg daily | 12 | false | MSS | 2026-03-15T05:35:58.034975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_779719 | REC_0004806 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 27 | 8.9 | 69 | female | 0 | 12 | 5 | 2 | entrectinib 600 mg daily | 11.8 | true | MSS | 2026-03-15T05:35:58.035203+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_345549 | REC_0004807 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 8.9 | 80 | male | 2 | 12 | 6.7 | 2 | sotorasib 960 mg daily | 15.5 | true | MSS | 2026-03-15T05:35:58.035436+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_337032 | REC_0004808 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 14.4 | 60 | male | 0 | 15 | 4.7 | 1 | sotorasib 960 mg daily | 18.1 | false | MSS | 2026-03-15T05:35:58.035672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_242048 | REC_0004809 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 29 | 7.6 | 58 | male | 0 | 35 | 3.7 | 6 | pembrolizumab 200 mg q3w | 8.7 | false | MSS | 2026-03-15T05:35:58.035904+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_721387 | REC_0004810 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 10.2 | 68 | female | 0 | 19 | 7.4 | 6 | osimertinib 80 mg daily | 10 | false | MSS | 2026-03-15T05:35:58.036234+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_865250 | REC_0004811 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 6.7 | 68 | female | 1 | 42 | 6.3 | 0 | carboplatin + paclitaxel + pembrolizumab | 18.3 | false | MSS | 2026-03-15T05:35:58.036537+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_319056 | REC_0004812 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 7.4 | 59 | female | 1 | 14 | 6.2 | 1 | entrectinib 600 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:58.036784+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_577508 | REC_0004813 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 13.7 | 80 | female | 0 | 19 | 3.2 | 6 | entrectinib 600 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:58.037021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_762789 | REC_0004814 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 7.7 | 54 | female | 0 | 15 | 7.1 | 7 | pembrolizumab 200 mg q3w | 7.4 | true | MSS | 2026-03-15T05:35:58.037253+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161615 | REC_0004815 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 24 | 12.2 | 71 | female | 1 | 5 | 6 | 0 | pembrolizumab 200 mg q3w | 48.5 | true | MSI-H | 2026-03-15T05:35:58.037485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_799363 | REC_0004816 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.1 | 64 | female | 0 | 59 | 8.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 12.1 | true | MSS | 2026-03-15T05:35:58.037718+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_464227 | REC_0004817 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 33 | 13 | 63 | female | 1 | 11 | 5.2 | 5 | entrectinib 600 mg daily | 6.3 | false | MSI-H | 2026-03-15T05:35:58.037959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511838 | REC_0004818 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 13.4 | 66 | female | 0 | 12 | 4.2 | 6 | entrectinib 600 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:35:58.038199+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_617023 | REC_0004819 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 14.1 | 62 | female | 0 | 21 | 5.4 | 2 | osimertinib 80 mg daily | 18 | true | MSS | 2026-03-15T05:35:58.038435+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_760678 | REC_0004820 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 7.5 | 69 | female | 1 | 31 | 6.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 23.1 | true | MSS | 2026-03-15T05:35:58.038663+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_469521 | REC_0004821 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 4.9 | 77 | female | 2 | 21 | 5.9 | 4 | pembrolizumab 200 mg q3w | 10.5 | false | MSS | 2026-03-15T05:35:58.038898+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_337997 | REC_0004822 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 10.3 | 76 | female | 1 | 4 | 5.9 | 5 | osimertinib 80 mg daily | 9.8 | true | MSI-H | 2026-03-15T05:35:58.039129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852695 | REC_0004823 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 15.2 | 69 | female | 0 | 11 | 6.5 | 6 | alectinib 600 mg BID | 4.7 | true | MSS | 2026-03-15T05:35:58.039364+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419009 | REC_0004824 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 19.8 | 60 | female | 1 | 12 | 6.1 | 7 | osimertinib 80 mg daily | 8.1 | true | MSS | 2026-03-15T05:35:58.039677+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_656615 | REC_0004825 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12 | 72 | male | 0 | 16 | 7.4 | 7 | sotorasib 960 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.039935+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_652344 | REC_0004826 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 22 | 12.7 | 72 | female | 1 | 16 | 3.8 | 0 | sotorasib 960 mg daily | 49.7 | false | MSS | 2026-03-15T05:35:58.040288+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_320086 | REC_0004827 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 13 | 69 | female | 1 | 9 | 7.5 | 2 | entrectinib 600 mg daily | 21.8 | true | MSS | 2026-03-15T05:35:58.040552+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_849370 | REC_0004828 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 5.6 | 67 | female | 1 | 44 | 4.1 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:58.040798+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271224 | REC_0004829 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 5.7 | 74 | female | 2 | 16 | 5.5 | 8 | entrectinib 600 mg daily | 10 | true | MSS | 2026-03-15T05:35:58.041039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_423223 | REC_0004830 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 21 | 10 | 75 | female | 2 | 6 | 5.3 | 0 | entrectinib 600 mg daily | 40.9 | true | MSI-H | 2026-03-15T05:35:58.041275+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_520930 | REC_0004831 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 18.9 | 59 | female | 0 | 24 | 6.2 | 6 | osimertinib 80 mg daily | 8.1 | false | MSI-H | 2026-03-15T05:35:58.041523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_211849 | REC_0004832 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 33 | 5.3 | 78 | male | 1 | 0 | 2.8 | 1 | osimertinib 80 mg daily | 4 | false | MSS | 2026-03-15T05:35:58.041775+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828900 | REC_0004833 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 3.2 | 55 | male | 0 | 54 | 3.1 | 6 | pembrolizumab 200 mg q3w | 14.1 | false | MSS | 2026-03-15T05:35:58.042035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_660415 | REC_0004834 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 32 | 8 | 68 | female | 1 | 15 | 7.3 | 4 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:58.042281+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_297945 | REC_0004835 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.7 | 79 | female | 2 | 12 | 4.4 | 7 | pembrolizumab 200 mg q3w | 8.8 | false | MSS | 2026-03-15T05:35:58.042513+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881857 | REC_0004836 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.7 | 73 | female | 1 | 72 | 3.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.6 | true | MSS | 2026-03-15T05:35:58.042743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315728 | REC_0004837 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.9 | 64 | female | 0 | 15 | 5.4 | 4 | alectinib 600 mg BID | 6.7 | true | MSS | 2026-03-15T05:35:58.043108+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_375792 | REC_0004838 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 12.2 | 84 | female | 3 | 12 | 4.3 | 7 | entrectinib 600 mg daily | 7.5 | false | MSS | 2026-03-15T05:35:58.043346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_937771 | REC_0004839 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.6 | 79 | female | 1 | 12 | 5.5 | 6 | alectinib 600 mg BID | 8.3 | true | MSI-H | 2026-03-15T05:35:58.043583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190384 | REC_0004840 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 7.9 | 64 | male | 0 | 19 | 5.9 | 2 | osimertinib 80 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:58.043816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747135 | REC_0004841 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 12.4 | 65 | female | 1 | 20 | 4.2 | 1 | sotorasib 960 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:58.044057+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381178 | REC_0004842 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 15.1 | 75 | female | 1 | 10 | 3.9 | 2 | osimertinib 80 mg daily | 22.8 | true | MSS | 2026-03-15T05:35:58.044354+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_609873 | REC_0004843 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 5.8 | 56 | female | 1 | 24 | 4.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.1 | false | MSS | 2026-03-15T05:35:58.044590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208711 | REC_0004844 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 20.2 | 59 | male | 1 | 16 | 6.2 | 6 | pembrolizumab 200 mg q3w | 13.6 | true | MSS | 2026-03-15T05:35:58.044826+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_612031 | REC_0004845 | Non-small cell lung cancer | Squamous cell carcinoma | III | None | 27 | 6.8 | 63 | male | 0 | 14 | 6.1 | 0 | carboplatin + paclitaxel + pembrolizumab | 27.5 | true | MSS | 2026-03-15T05:35:58.045058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_316914 | REC_0004846 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 22 | 8.1 | 70 | female | 2 | 17 | 4.2 | 0 | entrectinib 600 mg daily | 42.4 | true | MSS | 2026-03-15T05:35:58.045287+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_552550 | REC_0004847 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 16.7 | 73 | female | 2 | 9 | 5.8 | 7 | osimertinib 80 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:58.045522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_748161 | REC_0004848 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 30 | 6.7 | 72 | female | 1 | 12 | 4.9 | 2 | osimertinib 80 mg daily | 16.6 | true | MSS | 2026-03-15T05:35:58.045750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_256348 | REC_0004849 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 10.8 | 63 | female | 0 | 11 | 6.9 | 4 | alectinib 600 mg BID | 14.7 | false | MSS | 2026-03-15T05:35:58.045990+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934617 | REC_0004850 | Non-small cell lung cancer | Adenocarcinoma | III | None (PD-L1 high) | 22 | 6 | 65 | male | 1 | 20 | 8 | 0 | pembrolizumab 200 mg q3w | 41.9 | false | MSS | 2026-03-15T05:35:58.046292+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_939324 | REC_0004851 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 11.7 | 78 | female | 1 | 17 | 5.5 | 3 | osimertinib 80 mg daily | 5.5 | false | MSI-H | 2026-03-15T05:35:58.046525+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693241 | REC_0004852 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 6.3 | 55 | female | 1 | 32 | 5.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 26.6 | false | MSS | 2026-03-15T05:35:58.046757+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765456 | REC_0004853 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 5.5 | 69 | male | 1 | 17 | 4.9 | 8 | entrectinib 600 mg daily | 11.5 | true | MSS | 2026-03-15T05:35:58.046992+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698194 | REC_0004854 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 9 | 76 | female | 3 | 95 | 5.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 16.2 | false | MSS | 2026-03-15T05:35:58.047223+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_782006 | REC_0004855 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 10.6 | 76 | female | 2 | 12 | 5.5 | 10 | sotorasib 960 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:58.047458+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_339546 | REC_0004856 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 13.3 | 78 | female | 2 | 7 | 6.7 | 5 | entrectinib 600 mg daily | 8.6 | true | MSI-H | 2026-03-15T05:35:58.047688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_972610 | REC_0004857 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.3 | 81 | male | 1 | 14 | 3.7 | 7 | alectinib 600 mg BID | 7.9 | false | MSI-H | 2026-03-15T05:35:58.047924+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_350433 | REC_0004858 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 13.1 | 67 | female | 0 | 21 | 5.9 | 3 | pembrolizumab 200 mg q3w | 8.3 | true | MSS | 2026-03-15T05:35:58.048216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_442363 | REC_0004859 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12.4 | 64 | male | 1 | 17 | 4.9 | 4 | alectinib 600 mg BID | 6.6 | false | MSI-H | 2026-03-15T05:35:58.048469+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_690337 | REC_0004860 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 3.1 | 78 | male | 2 | 3 | 7.5 | 1 | pembrolizumab 200 mg q3w | 17.4 | false | MSS | 2026-03-15T05:35:58.048707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_392033 | REC_0004861 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 20.7 | 76 | female | 2 | 13 | 5.6 | 6 | osimertinib 80 mg daily | 11.7 | true | MSS | 2026-03-15T05:35:58.048942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_458816 | REC_0004862 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 7.5 | 76 | male | 2 | 11 | 4.9 | 3 | osimertinib 80 mg daily | 6.4 | false | MSS | 2026-03-15T05:35:58.049174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_439730 | REC_0004863 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 13.3 | 56 | male | 1 | 12 | 3.9 | 4 | sotorasib 960 mg daily | 6.6 | true | MSS | 2026-03-15T05:35:58.049503+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_388639 | REC_0004864 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 22 | 16 | 58 | female | 1 | 18 | 6 | 0 | osimertinib 80 mg daily | 42.4 | true | MSI-H | 2026-03-15T05:35:58.049750+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309730 | REC_0004865 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 9.7 | 62 | female | 1 | 11 | 8.2 | 8 | sotorasib 960 mg daily | 12.2 | false | MSS | 2026-03-15T05:35:58.049983+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_309766 | REC_0004866 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.6 | 62 | male | 0 | 41 | 6.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.2 | true | MSS | 2026-03-15T05:35:58.050221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340592 | REC_0004867 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 8.9 | 52 | male | 0 | 13 | 6.5 | 4 | sotorasib 960 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:58.050453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597343 | REC_0004868 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 9.7 | 63 | female | 1 | 14 | 5 | 5 | sotorasib 960 mg daily | 5.6 | true | MSS | 2026-03-15T05:35:58.050687+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_547930 | REC_0004869 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 4.1 | 69 | male | 0 | 39 | 5.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 10.3 | false | MSS | 2026-03-15T05:35:58.050920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477969 | REC_0004870 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 11.3 | 70 | female | 2 | 7 | 4.5 | 3 | entrectinib 600 mg daily | 8.9 | false | MSI-H | 2026-03-15T05:35:58.051182+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382747 | REC_0004871 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 11.6 | 65 | female | 0 | 17 | 5 | 1 | pembrolizumab 200 mg q3w | 20.1 | false | MSS | 2026-03-15T05:35:58.051455+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_726669 | REC_0004872 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 23 | 10.9 | 69 | female | 1 | 13 | 4.9 | 0 | sotorasib 960 mg daily | 39.9 | false | MSS | 2026-03-15T05:35:58.051696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_797805 | REC_0004873 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 15 | 5.4 | 59 | male | 1 | 25 | 4.5 | 7 | pembrolizumab 200 mg q3w | 19.2 | false | MSS | 2026-03-15T05:35:58.051931+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445764 | REC_0004874 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 16.9 | 65 | male | 1 | 13 | 6.3 | 1 | entrectinib 600 mg daily | 16.8 | false | MSI-H | 2026-03-15T05:35:58.052249+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_930676 | REC_0004875 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 11.4 | 61 | female | 1 | 12 | 5.4 | 1 | entrectinib 600 mg daily | 17.1 | true | MSS | 2026-03-15T05:35:58.052502+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223634 | REC_0004876 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.6 | 72 | female | 1 | 25 | 5.4 | 5 | alectinib 600 mg BID | 4 | true | MSS | 2026-03-15T05:35:58.052860+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_377907 | REC_0004877 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 8.8 | 73 | male | 1 | 10 | 5.8 | 5 | alectinib 600 mg BID | 14.1 | false | MSS | 2026-03-15T05:35:58.053105+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116231 | REC_0004878 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.4 | 65 | female | 1 | 31 | 7.3 | 7 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:35:58.053346+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_298836 | REC_0004879 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 6.8 | 59 | female | 1 | 31 | 6 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:35:58.053582+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800545 | REC_0004880 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 8.8 | 52 | male | 0 | 11 | 5.7 | 1 | sotorasib 960 mg daily | 13.5 | false | MSS | 2026-03-15T05:35:58.053816+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_772312 | REC_0004881 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 23 | 10.9 | 68 | female | 1 | 12 | 5.8 | 2 | pembrolizumab 200 mg q3w | 22.7 | false | MSI-H | 2026-03-15T05:35:58.054050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936378 | REC_0004882 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 8.7 | 64 | male | 1 | 16 | 6.4 | 2 | entrectinib 600 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:58.054284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_311853 | REC_0004883 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 18.3 | 77 | female | 1 | 0 | 5.1 | 8 | entrectinib 600 mg daily | 10.8 | true | MSI-H | 2026-03-15T05:35:58.054512+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_358667 | REC_0004884 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 8.6 | 61 | male | 1 | 8 | 4.4 | 6 | entrectinib 600 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:58.054743+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_463747 | REC_0004885 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 15.1 | 69 | female | 0 | 10 | 4.5 | 1 | osimertinib 80 mg daily | 27.2 | false | MSS | 2026-03-15T05:35:58.054975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_128699 | REC_0004886 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 13 | 78 | female | 2 | 24 | 4.5 | 4 | osimertinib 80 mg daily | 15.2 | true | MSI-H | 2026-03-15T05:35:58.055208+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115967 | REC_0004887 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 33 | 15.7 | 70 | female | 1 | 12 | 4.9 | 5 | alectinib 600 mg BID | 5.3 | true | MSS | 2026-03-15T05:35:58.055440+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371865 | REC_0004888 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 16.1 | 50 | male | 0 | 16 | 4.3 | 5 | alectinib 600 mg BID | 21 | false | MSI-H | 2026-03-15T05:35:58.055672+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881434 | REC_0004889 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 9.5 | 63 | male | 1 | 11 | 4.4 | 4 | osimertinib 80 mg daily | 13.9 | false | MSS | 2026-03-15T05:35:58.055956+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452849 | REC_0004890 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 6.9 | 68 | female | 1 | 51 | 5.8 | 8 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:58.056300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_786538 | REC_0004891 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 6.1 | 69 | female | 1 | 17 | 6 | 2 | osimertinib 80 mg daily | 18.6 | false | MSS | 2026-03-15T05:35:58.056545+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349344 | REC_0004892 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 10.9 | 75 | female | 1 | 24 | 6.8 | 6 | alectinib 600 mg BID | 13.8 | false | MSI-H | 2026-03-15T05:35:58.056783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_819785 | REC_0004893 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 11.4 | 48 | male | 0 | 3 | 5.8 | 7 | sotorasib 960 mg daily | 6.6 | false | MSS | 2026-03-15T05:35:58.057019+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_880766 | REC_0004894 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 20 | 17.1 | 65 | female | 1 | 13 | 5.9 | 2 | alectinib 600 mg BID | 22.6 | false | MSS | 2026-03-15T05:35:58.057261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683689 | REC_0004895 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 31 | 10.1 | 62 | female | 1 | 2 | 3.8 | 5 | entrectinib 600 mg daily | 9.2 | true | MSS | 2026-03-15T05:35:58.057496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_410544 | REC_0004896 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 23 | 17.9 | 75 | female | 2 | 13 | 3.9 | 6 | pembrolizumab 200 mg q3w | 8.4 | true | MSI-H | 2026-03-15T05:35:58.057728+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_630875 | REC_0004897 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 6.2 | 54 | female | 0 | 61 | 4.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 6.3 | true | MSS | 2026-03-15T05:35:58.057959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436857 | REC_0004898 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 7.2 | 52 | female | 0 | 37 | 4.3 | 2 | carboplatin + paclitaxel + pembrolizumab | 19 | false | MSS | 2026-03-15T05:35:58.058190+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_440543 | REC_0004899 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 27 | 5 | 63 | male | 1 | 58 | 2.5 | 3 | pembrolizumab 200 mg q3w | 13.7 | false | MSS | 2026-03-15T05:35:58.058423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_836997 | REC_0004900 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 25 | 3.6 | 86 | female | 1 | 16 | 6.7 | 1 | pembrolizumab 200 mg q3w | 15.1 | true | MSS | 2026-03-15T05:35:58.058656+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.